Optimal post-remission consolidation therapy in patients with AML
Acta Haematol. 2023 Nov 26. doi: 10.1159/000535457. Online ahead of print.ABSTRACTBACKGROUND: Despite recent advances, 40-85% of patients with acute myeloid leukemia (AML) achieve complete remission after intensive chemotherapy. However, without optimal treatment after remission, the risk of relapse remains high.SUMMARY: A variable number of consolidation cycles consisting of intermediate doses of cytarabine are the most commonly used regimens in low-intermediate risk AML, while patients at higher risk of relapse should consolidate response by proceeding to HSCT. Different post-consolidation (maintenance therapies) have de...
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Carlos Jimenez-Chillon Richard Dillon Nigel Russell Source Type: research

In Memoriam: Isaac Ben-Bassat (1937-2023) A Lifelong Legacy in Hematology
Acta Haematol. 2023 Nov 24:1-2. doi: 10.1159/000535013. Online ahead of print.NO ABSTRACTPMID:38008062 | DOI:10.1159/000535013 (Source: Acta Haematologica)
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Pia Raanani Source Type: research

Long-term Clinical Outcomes of Optimizing Combination Therapy for Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma: A Retrospective Study
CONCLUSIONS: Optimized treatment based on anatomical location, pulmonary function, and disease stage can improve long-term survival in patients with pulmonary MALT lymphoma.PMID:38008071 | DOI:10.1159/000535228 (Source: Acta Haematologica)
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Gi-June Min Chin Kook Rhee Tong Yoon Kim Young-Woo Jeon Joo Hyun O Byung-Ock Choi Gyeongsin Park Seok-Goo Cho Source Type: research

Optimal post-remission consolidation therapy in patients with AML
Acta Haematol. 2023 Nov 26. doi: 10.1159/000535457. Online ahead of print.ABSTRACTBACKGROUND: Despite recent advances, 40-85% of patients with acute myeloid leukemia (AML) achieve complete remission after intensive chemotherapy. However, without optimal treatment after remission, the risk of relapse remains high.SUMMARY: A variable number of consolidation cycles consisting of intermediate doses of cytarabine are the most commonly used regimens in low-intermediate risk AML, while patients at higher risk of relapse should consolidate response by proceeding to HSCT. Different post-consolidation (maintenance therapies) have de...
Source: Acta Haematologica - November 26, 2023 Category: Hematology Authors: Carlos Jimenez-Chillon Richard Dillon Nigel Russell Source Type: research

Complete response to donor lymphocyte infusion for primary hemophagocytic lymphohistiocytosis relapse after allogeneic hematopoietic cell transplantation
Acta Haematol. 2023 Nov 23. doi: 10.1159/000535449. Online ahead of print.ABSTRACTPrimary hemophagocytic lymphohistiocytosis (HLH) is a hyper-inflammatory disorder characterized by dysregulation of inflammatory cells and cytokine signalling. Although first-line treatment consisting of immunosuppressive therapy and allogeneic hematopoietic cell transplantation (HCT) is often curative, it remains unknown whether any effective therapies exist for disease relapse/progression after HCT. Here we present a case of a 29-year-old male with primary HLH that relapsed after HCT and subsequently achieved durable long disease-free survi...
Source: Acta Haematologica - November 23, 2023 Category: Hematology Authors: Rutvij A Khanolkar Nathan Kuehne Jan Storek Source Type: research

Complete response to donor lymphocyte infusion for primary hemophagocytic lymphohistiocytosis relapse after allogeneic hematopoietic cell transplantation
Acta Haematol. 2023 Nov 23. doi: 10.1159/000535449. Online ahead of print.ABSTRACTPrimary hemophagocytic lymphohistiocytosis (HLH) is a hyper-inflammatory disorder characterized by dysregulation of inflammatory cells and cytokine signalling. Although first-line treatment consisting of immunosuppressive therapy and allogeneic hematopoietic cell transplantation (HCT) is often curative, it remains unknown whether any effective therapies exist for disease relapse/progression after HCT. Here we present a case of a 29-year-old male with primary HLH that relapsed after HCT and subsequently achieved durable long disease-free survi...
Source: Acta Haematologica - November 23, 2023 Category: Hematology Authors: Rutvij A Khanolkar Nathan Kuehne Jan Storek Source Type: research

Complete response to donor lymphocyte infusion for primary hemophagocytic lymphohistiocytosis relapse after allogeneic hematopoietic cell transplantation
Acta Haematol. 2023 Nov 23. doi: 10.1159/000535449. Online ahead of print.ABSTRACTPrimary hemophagocytic lymphohistiocytosis (HLH) is a hyper-inflammatory disorder characterized by dysregulation of inflammatory cells and cytokine signalling. Although first-line treatment consisting of immunosuppressive therapy and allogeneic hematopoietic cell transplantation (HCT) is often curative, it remains unknown whether any effective therapies exist for disease relapse/progression after HCT. Here we present a case of a 29-year-old male with primary HLH that relapsed after HCT and subsequently achieved durable long disease-free survi...
Source: Acta Haematologica - November 23, 2023 Category: Hematology Authors: Rutvij A Khanolkar Nathan Kuehne Jan Storek Source Type: research

Acute febrile neutrophilic dermatosis (Sweet syndrome) in acute myeloid leukemia patients: a 28-year institutional experience
CONCLUSIONS: In AML patients with fever and unusual skin lesions, physicians may consider SS earlier which may shorten time to diagnosis. Future assessments of SS among patients treated with novel therapies for AML and molecular studies of biopsies may help further explain this dermatologic adverse event with earlier diagnosis and management of neutrophilic dermatoses in these patients.PMID:37989105 | DOI:10.1159/000535399 (Source: Acta Haematologica)
Source: Acta Haematologica - November 21, 2023 Category: Hematology Authors: Emily A Cowen Dulce M Barrios Melissa P Pulitzer Andrea P Moy Stephen W Dusza Susan De Wolf Mark B Geyer Alina Markova Source Type: research

Fluoroquinolone Prophylaxis During Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia - Pros and Cons
This article reviews the pros and cons of FQ prophylaxis mainly in patients with AL. Most current guidelines do not support universal prophylaxis but rather recommend a selective approach, weighing the benefits against the risks. This recommendation is based on the lack of mortality benefit reported in more recent meta-analyses. FQ prophylaxis was demonstrated to reduce bacteremia and febrile neutropenia episodes, although mostly in trials performed in low resistance settings (<20%), whereas current FQ resistance rates may reach 30-60%. Other disadvantages of FQ include potential adverse events, antibiotic resistance de...
Source: Acta Haematologica - November 21, 2023 Category: Hematology Authors: Tomer Hoffman Alaa Atamna Vladislav Litchevsky Irina Amitai Dafna Yahav Source Type: research

Acute febrile neutrophilic dermatosis (Sweet syndrome) in acute myeloid leukemia patients: a 28-year institutional experience
CONCLUSIONS: In AML patients with fever and unusual skin lesions, physicians may consider SS earlier which may shorten time to diagnosis. Future assessments of SS among patients treated with novel therapies for AML and molecular studies of biopsies may help further explain this dermatologic adverse event with earlier diagnosis and management of neutrophilic dermatoses in these patients.PMID:37989105 | DOI:10.1159/000535399 (Source: Acta Haematologica)
Source: Acta Haematologica - November 21, 2023 Category: Hematology Authors: Emily A Cowen Dulce M Barrios Melissa P Pulitzer Andrea P Moy Stephen W Dusza Susan De Wolf Mark B Geyer Alina Markova Source Type: research

Fluoroquinolone Prophylaxis During Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia - Pros and Cons
This article reviews the pros and cons of FQ prophylaxis mainly in patients with AL. Most current guidelines do not support universal prophylaxis but rather recommend a selective approach, weighing the benefits against the risks. This recommendation is based on the lack of mortality benefit reported in more recent meta-analyses. FQ prophylaxis was demonstrated to reduce bacteremia and febrile neutropenia episodes, although mostly in trials performed in low resistance settings (<20%), whereas current FQ resistance rates may reach 30-60%. Other disadvantages of FQ include potential adverse events, antibiotic resistance de...
Source: Acta Haematologica - November 21, 2023 Category: Hematology Authors: Tomer Hoffman Alaa Atamna Vladislav Litchevsky Irina Amitai Dafna Yahav Source Type: research

Acute febrile neutrophilic dermatosis (Sweet syndrome) in acute myeloid leukemia patients: a 28-year institutional experience
CONCLUSIONS: In AML patients with fever and unusual skin lesions, physicians may consider SS earlier which may shorten time to diagnosis. Future assessments of SS among patients treated with novel therapies for AML and molecular studies of biopsies may help further explain this dermatologic adverse event with earlier diagnosis and management of neutrophilic dermatoses in these patients.PMID:37989105 | DOI:10.1159/000535399 (Source: Acta Haematologica)
Source: Acta Haematologica - November 21, 2023 Category: Hematology Authors: Emily A Cowen Dulce M Barrios Melissa P Pulitzer Andrea P Moy Stephen W Dusza Susan De Wolf Mark B Geyer Alina Markova Source Type: research

Fluoroquinolone Prophylaxis During Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia - Pros and Cons
This article reviews the pros and cons of FQ prophylaxis mainly in patients with AL. Most current guidelines do not support universal prophylaxis but rather recommend a selective approach, weighing the benefits against the risks. This recommendation is based on the lack of mortality benefit reported in more recent meta-analyses. FQ prophylaxis was demonstrated to reduce bacteremia and febrile neutropenia episodes, although mostly in trials performed in low resistance settings (<20%), whereas current FQ resistance rates may reach 30-60%. Other disadvantages of FQ include potential adverse events, antibiotic resistance de...
Source: Acta Haematologica - November 21, 2023 Category: Hematology Authors: Tomer Hoffman Alaa Atamna Vladislav Litchevsky Irina Amitai Dafna Yahav Source Type: research

The role of hepcidin and an oral iron absorption test in identifying the root cause of iron-restricted anemia
CONCLUSION: OIAT differentiates between classical IDA and other types of anemia caused by abnormalities in iron absorption or systemic iron availability. Additionally, elevated hepcidin in patients with oral iron malabsorption could indicate IRIDA.PMID:37972576 | DOI:10.1159/000535275 (Source: Acta Haematologica)
Source: Acta Haematologica - November 16, 2023 Category: Hematology Authors: Roberta Loveikyte Yascha van den Berg Andrea van der Meulen-de Jong Lodewijk Thomas Vlasveld Source Type: research

The role of hepcidin and an oral iron absorption test in identifying the root cause of iron-restricted anemia
CONCLUSION: OIAT differentiates between classical IDA and other types of anemia caused by abnormalities in iron absorption or systemic iron availability. Additionally, elevated hepcidin in patients with oral iron malabsorption could indicate IRIDA.PMID:37972576 | DOI:10.1159/000535275 (Source: Acta Haematologica)
Source: Acta Haematologica - November 16, 2023 Category: Hematology Authors: Roberta Loveikyte Yascha van den Berg Andrea van der Meulen-de Jong Lodewijk Thomas Vlasveld Source Type: research